| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax |
NCT05303584: Heterologous Boost Immunization With Ad5-nCoV After Three-dose Priming With an Inactivated SARS-CoV-2 Vaccine |
|
|
| Active, not recruiting | 4 | 360 | RoW | Ad5-nCoV-IH, aerosolized Ad5-nCoV, Convidecia, Ad5-nCoV-IM, intramuscular Ad5-nCoV, CoronaVac | Jiangsu Province Centers for Disease Control and Prevention | COVID-19 | 06/22 | 03/23 | | |
ChiCTR2200057278: Immunogenicity Study on Booster Immunization of Different COVID-19 Vaccines |
|
|
| Recruiting | 4 | 1000 | | Intramuscular Ad5-nCoV ;Aerosol Ad5-nCoV ;Intramuscular ZF2001 ;Intramuscular inactivated vaccine ;Aerosol Ad5-nCoV | Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China; Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, Ministry of Science and Technology of China | COVID-19 | | | | |
NCT05855408: Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults |
|
|
| Not yet recruiting | 4 | 10000 | RoW | Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1, SYS6006 | Jiangsu Province Centers for Disease Control and Prevention | COVID-19 | 05/24 | 12/24 | | |
ChiCTR2300073367: A clinical trial of Convidecia air in a stable population with mild to moderate chronic obstructive pulmonary disease |
|
|
| Recruiting | 4 | 150 | | Inoculation of recombinant novel coronavirus vaccine for inhalation (adenovirus type 5 vector) ;Inoculate 0.9% sodium chloride injection ;Inoculation of inactivated novel coronavirus vaccine (Vero cells) ;Inoculation of recombinant novel coronavirus vaccine for inhalation (adenovirus type 5 vector) ;Inoculate 0.9% sodium chloride injection ;Inoculation of inactivated novel coronavirus vaccine (Vero cells) | The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University, Cansino Biologics Inc. | COVID-19 | | | | |
NCT04540419: Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 |
|
|
| Completed | 3 | 500 | RoW | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo | NPO Petrovax, CanSino Biologics Inc. | Covid19 | 06/21 | 07/21 | | |
NCT04526990: Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above |
|
|
| Completed | 3 | 44247 | RoW | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo | CanSino Biologics Inc., Beijing Institute of Biotechnology | COVID-19 | 08/21 | 10/22 | | |
ChiCTR2100044249: Global phase III trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in adults 18 years of age and older |
|
|
| Recruiting | 3 | 40000 | | 0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular | Canadian Center for Vaccinology Dalhousie University/IWK Health Centre; CanSino Biologics Inc., Self-financing | Novel Coronavirus Pneumonia (COVID-19) | | | | |
NCT05204589: Heterologous Boost Immunization With an Aerosolised Ad5-nCoV After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine |
|
|
| Active, not recruiting | 3 | 10420 | RoW | Aerosolized Ad5-nCoV, Inactivated SARS-CoV-2 vaccine | Jiangsu Province Centers for Disease Control and Prevention, Anhui Provincial Center for Disease Control and Prevention, Shandong Province Centers for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, Yunnan Center for Disease Control and Prevention, Chongqing Center for Disease Control and Prevention | COVID-19 | 04/22 | 09/22 | | |
NCT05124561: Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) |
|
|
| Withdrawn | 3 | 13000 | NA | Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), Placebo | CanSino Biologics Inc., Beijing Institute of Biotechnology | COVID-19 | 04/22 | 08/22 | | |
NCT05169008: A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents |
|
|
| Terminated | 3 | 91 | RoW | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH) | CanSino Biologics Inc., Beijing Institute of Biotechnology | COVID-19 | 01/23 | 01/23 | | |
NCT05517642: IH Convidecia as Second Booster Dose Against Breakthrough Infections |
|
|
| Completed | 3 | 540 | RoW | Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), mRNA vaccine BNT162b2 (Pfizer) | CanSino Biologics Inc. | COVID-19 | 05/23 | 05/23 | | |
NCT05005156: Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older. |
|
|
| Recruiting | 2b | 876 | RoW | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) | Fundación Huésped, Canadian Center for Vaccinology, CanSino Biologics Inc., Hospital Fernandez | Covid19 | 09/22 | 09/22 | | |
| Active, not recruiting | 2b | 450 | RoW | Ad5-nCov | Fundación Huésped, Dalhousie University, CanSino Biologics Inc. | COVID-19 Vaccine | 11/22 | 04/23 | | |
NCT05330871: Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years. |
|
|
| Active, not recruiting | 2 | 410 | RoW | 1 Nebulized inhalation for booster groups, Recombinant COVID-19 Vaccine for Inhalation, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for booster groups, 4 Nebulized inhalation for booster groups, 5 Intramuscular injection for booster groups, Recombinant Corona Virus Vaccine (Adenovirus Type 5 Vector), 6 Intramuscular injection for booster groups, 7 Intramuscular injection for booster groups, 8 Intramuscular injection for booster groups, Inactivated COVID-19 Vaccine, 9 Intramuscular injection for booster groups, 10 Intramuscular injection for booster groups, 11 Nebulized inhalation for booster groups, 12 Nebulized inhalation for booster groups, 13 Nebulized inhalation for booster groups, 14 Nebulized inhalation for booster groups, 15 Intramuscular injection for booster groups, 16 Intramuscular injection for booster groups, 17 Intramuscular injection for booster groups, 18 Intramuscular injection for booster groups, 19 Intramuscular injection for booster groups, 20 Intramuscular injection for booster groups, 21 Nebulized inhalation for primary groups, 22 Nebulized inhalation for primary groups, 23 Nebulized inhalation for primary groups, 24 Nebulized inhalation for primary groups | Seventh Medical Center of PLA General Hospital | COVID-19 | 06/22 | 05/23 | | |
NCT04840992: Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation |
|
|
| Completed | 1/2 | 840 | RoW | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo for Inhalation, Placebo | CanSino Biologics Inc., Beijing Institute of Biotechnology, Jiangsu Province Centers for Disease Control and Prevention | COVID-19 | 07/22 | 08/22 | | |
NCT05043259: Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine |
|
|
| Active, not recruiting | 1/2 | 420 | RoW | inactive SARS-CoV-2 vaccine (Vero cell), Low dose aerosolized Ad5-nCoV, High dose aerosolized Ad5-nCoV | Jiangsu Province Centers for Disease Control and Prevention | COVID-19 | 08/22 | 12/22 | | |
NCT04552366: A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults |
|
|
| Completed | 1 | 149 | RoW | Ad5-nCoV | Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, Zhongnan Hospital | COVID-19 | 12/20 | 04/21 | | |
NCT04916886: A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups. |
|
|
| Completed | N/A | 2021 | RoW | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml | CanSino Biologics Inc., Jiangsu Province Centers for Disease Control and Prevention | COVID-19 | 07/22 | 07/22 | | |
NCT05886790: A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes |
|
|
| Recruiting | N/A | 450 | RoW | Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation, Ad5-NCO5T-IH, Bivalent COVID-19 mRNA Vaccine, mbO5, Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation, Ad5-nCoV-IH | Zhongnan Hospital, Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | COVID-19 | 12/23 | 05/24 | | |
| Recruiting | N/A | 600 | RoW | inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | COVID-19 | 03/23 | 12/24 | | |
| diphtheria, tetanus and pertussis vaccine infant (DTcP infant) / CanSino |
NCT05951725: A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) |
|
|
| Active, not recruiting | 3 | 2520 | RoW | Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP), Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP, Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib, DTcP, DTaP-IPV-Hib | CanSino Biologics Inc. | Diphtheria, Tetanus and Acellular Pertussis | 08/24 | 08/24 | | |
ChiCTR2000031510: Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP) |
|
|
| Not yet recruiting | 1 | 400 | | 0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular ;0.5ml, one dose each in 3, 4, 5 month ;0.5ml, one dose each in 3, 4, 5 month ;0.5ml, one dose each in 3, 4, 5 month ;0.5ml, one dose each in 2, 3, 4 month ;0.5ml, one dose each in 2, 3, 4 month ;0.5ml, one dose each in 2, 3, 4 month | He'nan Center for Disease Control and Prevention; CanSino Biologics Inc., Self-finance | Diphtheria, Tetanus, Pertussis | | | | |
| 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i) / Sinovac, CanSino |
NCT04841369: Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) |
|
|
| Completed | 3 | 3420 | RoW | 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, PCV13i, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, Prevnar | CanSino Biologics Inc., Henan Center for Disease Control and Prevention | Pneumococcal Infections, Streptococcal Infections, Bacterial Infections | 03/22 | 09/22 | | |
ChiCTR2000031515: Phase I Clinical Trial of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197, TT) |
|
|
| Not yet recruiting | 1 | 237 | | 0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular ;0.5ml, once by Intramuscular ;0.5ml, one dose each in 0, 2month by Intramuscular ;0.5ml, one dose each in 0, 1, 2month by Intramuscular ;0.5ml, one dose each in 0, 2, 4month by Intramuscular ;0.5ml, one dose each in 0, 2, 4month by Intramuscular | He'nan Center for Disease Control and Prevention; CanSino Biologics Inc., Self-finance | Pneumonia | | | | |
NCT05092386: Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine |
|
|
| Recruiting | 1 | 310 | RoW | Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13), Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13) | Sinovac Life Sciences Co., Ltd. | Pneumococcal Infections | 06/24 | 06/24 | | |
| Recruiting | 1 | 140 | RoW | Sinovac PCV13, PREVNAR 13 | Sinovac Research and Development Co., Ltd. | Pneumococcal Infectious Disease | 09/24 | 04/25 | | |
| Convidecia Air (Ad5-nCoV-IH) / CanSino |
NCT05442684: A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine |
|
|
| Withdrawn | 3 | 1350 | NA | Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation, mRNA-based COVID-19 vaccine | CanSino Biologics Inc. | COVID-19 | 03/23 | 06/23 | | |
| COVID-19 mRNA vaccine / CanSino |
NCT05373472: Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older |
|
|
| Active, not recruiting | 2 | 150 | RoW | COVID-19 mRNA vaccine, Placebo | CanSino Biologics Inc. | COVID-19 | 12/23 | 12/23 | | |
NCT05373485: Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older |
|
|
| Active, not recruiting | 1 | 150 | RoW | COVID-19 mRNA vaccine, Placebo | CanSino Biologics Inc. | COVID-19 | 11/23 | 12/23 | | |
| recombinant pneumococcal protein vaccine (PBPV) / CanSino |
| Recruiting | 1 | 120 | | received three doses at 0, 2, 4 month ;received three doses at 0, 2, 4 month ;received three doses at 0, 2, 4 month | Henan Center for Disease Control and Prevention; CanSino Biologics Inc., Self-finance | Pneumonia | | | | |
NCT05622942: Clinical Trial of Recombinant Pneumococcal Protein Vaccine |
|
|
| Active, not recruiting | 1 | 60 | RoW | PBPV, PPV23 | CanSino Biologics Inc. | Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections | 12/23 | 12/23 | | |
